Sumitomo Pharma America News and Activities

Sumitomo Pharma America is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1476);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 20 subsidiaries including Aetion, Aramis Biosciences and Asahi Chemical.

They are in:

• Biotechnology52%
• Chemicals24%
• Other24%

View the org chart displaying its 23 main executives

Most searched biographies at Sumitomo Pharma America

• Tsutomu Nakagawa, Chief Executive Officer
• Tara Soni, General Counsel
• Ron Gimbel, Chief Financial Officer and Director

Popular executive movements at Sumitomo Pharma America

• Shigeyuki Nishinaka, Director, has left the company  (posted on November 3 2025).

Create your alert
to follow the executive moves at Sumitomo Pharma America.

Sumitomo Chemical has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Sumitomo Pharma America

• Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
• Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
• Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA®
• Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
• Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
• Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual Meeting
• Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
• Sumitomo Pharma America Newsroom - News ReleasesBack ButtonFilter Button
• News | Sumitovant
• View more press releases Close

Social media about Sumitomo Pharma America

• Sumitomo Pharma America on Wikipedia, Google News & Yahoo Finance
• Sumitomo Pharma America on LinkedIn, X (Twitter) & YouTube